secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018788
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q2 net loss widens to $37.7M; reports positive Phase 2 COVID-19 data, $200M royalty sale
--------------------------------------------------------------------------------

- Net loss $37.7M ($1.79 loss/diluted share) vs $33.6M loss ($1.63) YoY; revenue $17.8M from HCV royalties.
- Positive Phase 2 SPRINT data for EDP-235 (COVID-19): met primary endpoint; 400mg showed symptom improvement vs placebo.
- Sold 54.5% of future MAVYRET royalties to OMERS for $200M upfront; cash runway extended into calendar 2026.
- Cash and marketable securities $225.1M at March 31, 2023; plus remaining 45.5% royalty stream after cap.
- Phase 1 data for RSV L-protein inhibitor EDP-323 expected in June; dual hMPV/RSV candidate selection in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023018788/0000950170-23-018788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023018788/enta-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer